Robert59
Well-known Member
Gilead Sciences Inc has priced its COVID-19 drug candidate remdesivir at $2,340 for a five-day treatment in the United States and some other developed countries, potentially reflecting looming competition from a cheap steroid.
The price tag is below the $5,080 per course recommendation by U.S. drug pricing research group, the Institute for Clinical and Economic Review (ICER), last week.
https://www.yahoo.com/finance/news/gilead-prices-covid-19-drug-111703247.html
The price tag is below the $5,080 per course recommendation by U.S. drug pricing research group, the Institute for Clinical and Economic Review (ICER), last week.
https://www.yahoo.com/finance/news/gilead-prices-covid-19-drug-111703247.html